554P Phase I clinical trial of OBP-301, a novel telomerase-specific oncolytic virus, in combination with radiotherapy in esophageal cancer patients

OBP-301 is a novel condition-restricted, replication-competent adenovirus derived from human adenovirus type 5 that incorporates a human telomerase reverse transcriptase (hTERT) promoter. This construct causes tumor-specific viral replication and lytic death of a variety of cancer cells, and safety of OBP-301 monotherapy has been confirmed in patients with solid tumor in phase I clinical trial. We conducted phase I clinical trial to evaluate...